FindTrial
Sign In

MDNA11

DRUG2 trials

Sponsors

Medicenna Therapeutics Inc., Medicenna Therapeutics, Inc.

Conditions

Acral MelanomaAdvanced Solid TumorAdvanced Solid TumorsBasal Cell CarcinomaBladder CancerCancer With A High Tumor Mutational BurdenCervical CancerCervical Cancers

Phase 1

A Beta-only IL-2 ImmunoTherapY Study
RecruitingNCT05086692
Medicenna Therapeutics, Inc.Acral Melanoma, Advanced Solid Tumor, Basal Cell Carcinoma +34
Start: 2021-08-27End: 2026-12-30Target: 115Updated: 2025-07-09
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
RecruitingCTIS2023-507536-21-00
Medicenna Therapeutics Inc.Advanced Solid Tumors
Start: 2024-10-04Target: 93Updated: 2025-09-19

Related Papers

Abstract CT047: Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors
Cancer Research2025-04-251 citations
Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors
Cancer Research2024-04-053 citations
743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist
Regular and Young Investigator Award Abstracts2022-11-011 citations
744 Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist
Regular and Young Investigator Award Abstracts2022-11-01